Utsikt
Senior Member (Voting Rights)
Potential being the key word here. In reality, we have no clue.Fluge and Mella, the principal investigators of the DARATUMUMAB trial, explicitly discuss autoantibodies against beta-receptors as a potential pathomechanism in ME/CFS. You can read it here:
Lots of things can induce lots of effects in rats, and it rarely translates to humans. Did they use serum from both healthy and diseased controls to show that this effect is unique to ME/CFS serum?Yes, the Mitodicure drug is largely based on hypotheses. However, Wirth did show that serum from ME/CFS patients induced muscle weakness in rats, and the experimental drug was able to reverse that effect. So at least in rats, there seems to be a measurable effect.
You might want to take a look at this response by Jonathan Edwards about the fundamental issues with molecular mimicry theories.Another possible mechanism is molecular mimicry. Scheibenbogen published a paper on this. Autoantibodies can persist even after the virus is gone, because the immune system has been “trained” to react to the body’s own proteins.
What does mimicry actually mean? Does it mean that they different parts can interact with each other? And does that even matter?
The basic idea is that if a microbial protein is sufficiently similar to a host protein then the immune system can make the mistake of mounting a response to the microbial protein that also reacts with self protein. So if the microbial protein has a peptide sequence with letters for amino acids:
AQTGES
and there is a host protein with a peptide
AQGGES
then maybe T cells reacting to AQTGES will help B cells make antibody to AQGGES.
The only problem is...
I’m asking questions because you seem rather convinced about this hypothesis, so if I can understand the evidence you’re basing your assessment on, I might get a better understanding of why you are convinced or hopeful.I can see that I’m probably not going to convince you any further![]()